Press Releases
MFX, Tolemy Bio and Aminoacids.com Partner to Deliver Model-Driven Media Optimization for Cell and Gene Therapies
Joint research project to develop computationally predicted media supplements to improve T cell expansion for ex vivo therapies
Stevenage, UK, Cambridge, Uk and St Paul, Minnesota, Dec 5, 2024 – MFX a UK based developer of advanced bioreactor technology for cell culture and cell therapy manufacturing, Tolemy Bio, a leader in custom cell culture media design using AI and ML, and Aminoacids.com, a specialist in analytics for media quantification, today announce a joint development project to deliver AI derived novel media formulations to optimize T-cell culture performance for cell and gene therapy development.
The collaboration will leverage MFX’s Cyto Engine™ high-throughput process development platform, Tolemy’s expertise in AI-enabled media formulation prediction, and Aminoacids.com’s media analytics capabilities to study T-cell cultures. The goal is to develop and test computationally predicted media supplements that can significantly improve T-cell expansion while maintaining viability and functionality – critical attributes for advancing next-generation cell and gene therapies.
“By bringing together MFX’s scalable bioreactor technology, Tolemy’s modelling capabilities, and Aminoacids.com’s analytics expertise, we aim to transform T-cell culture protocols and unlock new levels of process performance for cell and gene therapy developers,” says Antoine Espinet, CEO of MFX
Initial studies in the Cyto Engine™ platform have already demonstrated the potential for optimising T-cell culture rapidly by utilising bio-adaptive feeding strategy (https://mfx.bio/data/). The partners will build on these early successes to develop a comprehensive, AI-powered culture optimization approach.
“This collaboration paves the way for significant advancements in T-cell manufacturing performance through bespoke media optimisation. By combining Tolemy’s advanced media design, Aminoacids.com’s spent media profiling, and MFX’s unique bioreactor technology, we are able to push the boundaries of what is achievable with current manufacturing systems.,” explains Alex Ward, Co-founder of Tolemy Bio. “The Cyto Engine™ bioreactors further provide an ideal testbed to generate the culture data, with completely novel process parameters, and quickly evaluate novel media candidates and validate the benefits.”
“We’re excited to contribute our expertise in media analytics and spent media testing to this groundbreaking collaboration,” says Mark Whittaker, President of AminoAcids.com.
“By working closely with MFX and Tolemy Bio, we can generate in depth datasets that can be utilised to create custom media solutions that unlock new possibilities for T cell culture and advanced therapy development.“
The joint project aims to discover and test the impact of a novel media supplement that can be readily integrated into existing T cell culture processes. The partners plan to share initial findings in early 2025.
About Tolemy Bio
Tolemy Bio, based in Cambridge, UK, develops precision engineered, custom cell culture media formulations for the cell and gene therapy (CGT) industry, leveraging advanced AI and machine learning techniques. Through its advanced computational approach, Tolemy is able to specifically engineer cell metabolism in ways that are not achievable with current methods. Tolemy’s data driven media solutions offer the potential to deliver better CGT products faster than ever before, closing the gap on patient access to these life-saving treatments. To find out more, visit www.tolemy.bio or follow us on LinkedIn.
About AminoAcids.com
Scientific Research Consortium, Inc, doing business as AminoAcids.com, is a Roseville, MN based testing laboratory focused on analysis of amino acids. B-vitamins, and lipids in complex media. Since 1994, AminoAcids.com has assisted companies and researchers in the cell culture media, biopharma, food and feeds, and biofuels industries in developing, optimizing and quality testing nutritional components in complex matrices. Accredited under ISO 17025 and CLIA (Clinical Laboratory Improvement Act) for complex testing, AminoAcids.com is a leader in developing and executing validated testing programs for researchers worldwide. To find out more, visit www.AminoAcids.com.